Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004

被引:52
|
作者
Wolfsperger, Marcus
Greil, Waldemar
Roessler, Wulf
Grohmann, Renate
机构
[1] Psychiat Privatklin Sanat Kilchberg, CH-8802 Kilchberg, Switzerland
[2] Psychiat Univ Klin, D-80336 Munich, Germany
[3] Psychiat Univ Klin, CH-8008 Zurich, Switzerland
关键词
mania; prescription; anticonvulsants; lithium; antipsychotics; antidepressants;
D O I
10.1016/j.jad.2006.08.017
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: In a cross-section approach we investigated prescription practice in acute mania in 63 German, Swiss and Austrian hospitals between 1994 and 2004. Methods: Our data were gathered from a large drug safety program (AMSP) within which on two reference days each year all administered drugs are recorded. For the present study, all cases with a primary diagnosis of acute euphoric mania (n = 129 1) or mixed-state mania (n = 143) were identified. Prescription rates from two periods, 1994 to 1999 and 2000 to 2004, were compared. Results: In euphoric mania, prescription of lithium decreased by about one-fifth (43.3% to 34.5%, p < 0.01), while prescription of anticonvulsants increased by one-half (from 40.0% to 60.7%, p < 0.001). Administration of atypical antipsycbotics more than doubled (18.5% to 43.9%, p < 0.001), while use of typical antipsychotics decreased significantly (56.9% to 27.8%, p < 0.001). Overall prescription rates of antipsychotics (79.6% vs. 81.6%) and antidepressants (14.0% vs. 15.5%) remained stable, while administration of tranquilizers increased significantly (26.3% to 34.3%, p < 0.01). In mixed-state mania, similar trends over time to those seen in euphoric mania were observed for lithium (43.2% to 33.3%), anticonvulsants (50.0% to 69.7%, p < 0.05) and tranquilizers (22.7% to 40.4%). Prescription rates of antipsychotics slightly increased (63.6% to 72.7%), while prescription of antidepressants slightly decreased (54.5% to 46.5%). Polypharmacy was a common phenomenon: patients with euphoric mania were treated with a mean number of 2.9 +/- 1.2 psychotropic agents, and patients with mixed-state mania with 3.3 +/- 1.5 psychotropic agents. Both groups showed a significant increase over time. Second-generation atypical antipsychotics were adopted quite rapidly for the treatment of acute mania considering the availability of the scientific evidence at that time. Off-label use was a common phenomenon. Deviations from recommended guidelines were found mainly in the use of antidepressant and antipsychotic drugs both in mixed-state and euphoric mania. Conclusions: Naturalistic prescription studies like this may encourage a critical scrutiny of clinical treatment habits and may also drive further research thus moderating potential differences between evidence-based knowledge and everyday clinical practice. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:9 / 17
页数:9
相关论文
共 26 条
  • [1] Psychopharmacological treatment of 1650 in-patients with acute mania-data from the AMSP study
    Kleimann, Alexandra
    Schrader, Viktoria
    Stuebner, Susanne
    Greil, Waldemar
    Kahl, Kai G.
    Bleich, Stefan
    Grohmann, Renate
    Frieling, Helge
    Toto, Sermin
    JOURNAL OF AFFECTIVE DISORDERS, 2016, 191 : 164 - 171
  • [2] The Mania Pathway Protocol: An Application of Evidence-Based Interventions for the Treatment of Acute Mania on an Inpatient Psychiatric Unit
    Adri, Avishay A.
    JOURNAL OF THE AMERICAN PSYCHIATRIC NURSES ASSOCIATION, 2021, 27 (06) : 496 - 501
  • [3] Treatment of acute mania with topiramate in hospitalized patients
    Bozikas, VP
    Petrikis, P
    Kourtis, A
    Youlis, P
    Karavatos, A
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2002, 26 (06) : 1203 - 1206
  • [4] Pharmacological treatment of psychiatric comorbidity in patients with refractory epilepsy
    Karouni, Mohamad
    Henning, Oliver
    Larsson, Pal G.
    Johannessen, Svein I.
    Landmark, Cecilie Johannessen
    EPILEPSY & BEHAVIOR, 2013, 29 (01) : 77 - 81
  • [5] The pattern of pharmacological treatment of bipolar patients discharged from psychiatric units in Poland
    Jaracz, Jan
    Tetera-Rudnicka, Edyta
    Bierejszyk, Magdalena
    Witczyk, Kaja
    Raczynska, Agnieszka
    Nowak, Wojciech
    Pisarczyk, Anna
    Wozniak, Krzysztof
    Czernas, Wojciech
    Moniakowski, Adam
    Jaracz, Krystyna
    PHARMACOLOGICAL REPORTS, 2018, 70 (04) : 694 - 698
  • [6] Pharmacological management of acute agitation in psychiatric patients: an umbrella review
    Uribe, Erasmo Saucedo
    Rodriguez, Cynthia Alejandra Bravo
    Juarez, Miguel Emanuel Navarrete
    Juarez, Samantha Medrano
    Lucio, Rodrigo Huereca
    Guzman, Kevin Eduardo Rojas
    Carrillo, Luis Carlos Lozano
    BMC PSYCHIATRY, 2025, 25 (01)
  • [7] Early Improvement Predicts Treatment Outcomes for Patients With Acute Mania: A Naturalistic Study in Taiwan
    Li, Dian-Jeng
    Lin, Ching-Hua
    Lu, Mei-Jou
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2017, 37 (04) : 435 - 440
  • [8] Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders
    Bridler, Rene
    Haeberle, Anne
    Mueller, Sabrina T.
    Cattapan, Katja
    Grohmann, Renate
    Toto, Sermin
    Kasper, Siegfried
    Greil, Waldemar
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 (06) : 763 - 772
  • [9] The impact of affective temperaments on clinical and functional outcome of Bipolar I patients that initiated or changed pharmacological treatment for mania
    Perugi, G.
    Cesari, D.
    Vannucchi, G.
    Maccariello, G.
    Barbuti, M.
    De Bartolomeis, A.
    Fagiolini, A.
    Maina, G.
    PSYCHIATRY RESEARCH, 2018, 261 : 473 - 480
  • [10] Revisiting the association between treatment with antidepressants and mania: A nationwide within-individual study of 3554 patients with bipolar disorder
    Jefsen, Oskar Hougaard
    Rohde, Christopher
    Ostergaard, Soren Dinesen
    BIPOLAR DISORDERS, 2023, 25 (07) : 583 - 591